Literature DB >> 12444207

A role for uric acid in the progression of renal disease.

Duk-Hee Kang1, Takahiko Nakagawa, Lili Feng, Susumu Watanabe, Lin Han, Marilda Mazzali, Luan Truong, Raymond Harris, Richard J Johnson.   

Abstract

Hyperuricemia is associated with renal disease, but it is usually considered a marker of renal dysfunction rather than a risk factor for progression. Recent studies have reported that mild hyperuricemia in normal rats induced by the uricase inhibitor, oxonic acid (OA), results in hypertension, intrarenal vascular disease, and renal injury. This led to the hypothesis that uric acid may contribute to progressive renal disease. To examine the effect of hyperuricemia on renal disease progression, rats were fed 2% OA for 6 wk after 5/6 remnant kidney (RK) surgery with or without the xanthine oxidase inhibitor, allopurinol, or the uricosuric agent, benziodarone. Renal function and histologic studies were performed at 6 wk. Given observations that uric acid induces vascular disease, the effect of uric acid on vascular smooth muscle cells in culture was also examined. RK rats developed transient hyperuricemia (2.7 mg/dl at week 2), but then levels returned to baseline by week 6 (1.4 mg/dl). In contrast, RK+OA rats developed higher and more persistent hyperuricemia (6 wk, 3.2 mg/dl). Hyperuricemic rats demonstrated higher BP, greater proteinuria, and higher serum creatinine than RK rats. Hyperuricemic RK rats had more renal hypertrophy and greater glomerulosclerosis (24.2 +/- 2.5 versus 17.5 +/- 3.4%; P < 0.05) and interstitial fibrosis (1.89 +/- 0.45 versus 1.52 +/- 0.47; P < 0.05). Hyperuricemic rats developed vascular disease consisting of thickening of the preglomerular arteries with smooth muscle cell proliferation; these changes were significantly more severe than a historical RK group with similar BP. Allopurinol significantly reduced uric acid levels and blocked the renal functional and histologic changes. Benziodarone reduced uric acid levels less effectively and only partially improved BP and renal function, with minimal effect on the vascular changes. To better understand the mechanism for the vascular disease, the expression of COX-2 and renin were examined. Hyperuricemic rats showed increased renal renin and COX-2 expression, the latter especially in preglomerular arterial vessels. In in vitro studies, cultured vascular smooth muscle cells incubated with uric acid also generated COX-2 with time-dependent proliferation, which was prevented by either a COX-2 or TXA-2 receptor inhibitor. Hyperuricemia accelerates renal progression in the RK model via a mechanism linked to high systemic BP and COX-2-mediated, thromboxane-induced vascular disease. These studies provide direct evidence that uric acid may be a true mediator of renal disease and progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444207     DOI: 10.1097/01.asn.0000034910.58454.fd

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  294 in total

Review 1.  Metabolic control of renin secretion.

Authors:  János Peti-Peterdi; Haykanush Gevorgyan; Lisa Lam; Anne Riquier-Brison
Journal:  Pflugers Arch       Date:  2012-06-23       Impact factor: 3.657

2.  The relationship between serum uric acid and chronic kidney disease among Appalachian adults.

Authors:  Loretta Cain; Anoop Shankar; Alan M Ducatman; Kyle Steenland
Journal:  Nephrol Dial Transplant       Date:  2010-05-25       Impact factor: 5.992

Review 3.  Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke.

Authors:  Laura Llull; Sergio Amaro; Ángel Chamorro
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

4.  Uric acid, hypertension, and chronic kidney disease among Alaska Eskimos: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study.

Authors:  Stacey E Jolly; Mihriye Mete; Hong Wang; Jianhui Zhu; Sven O E Ebbesson; V Saroja Voruganti; Anthony G Comuzzie; Barbara V Howard; Jason G Umans
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-01-04       Impact factor: 3.738

5.  Uric acid and insulin sensitivity and risk of incident hypertension.

Authors:  John P Forman; Hyon Choi; Gary C Curhan
Journal:  Arch Intern Med       Date:  2009-01-26

6.  Uric acid level and erectile dysfunction in patients with coronary artery disease.

Authors:  Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay
Journal:  J Sex Med       Date:  2013-09-25       Impact factor: 3.802

7.  Hyperuricemia is associated with progression of IgA nephropathy.

Authors:  Ali Bakan; Alihan Oral; Omer Celal Elcioglu; Mumtaz Takir; Osman Kostek; Abdullah Ozkok; Semih Basci; Abdullah Sumnu; Savas Ozturk; Murat Sipahioglu; Aydın Turkmen; Luminita Voroneanu; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-03-12       Impact factor: 2.370

8.  Protective potential of Opuntia microdasys flower decoction on fructose-alloxan-induced diabetic rats on kidney and pancreas: chemical and immunohistochemical analyses.

Authors:  Hassiba Chahdoura; Aida Khlifi; Jihéne Ben Lamine; Borhane Eddine Cherif Ziani; Khawla Adouni; Safia El Bok; Zohra Haouas; Fadoua Neffati; Abdelfattah Zakhama; Guido Flamini; Lotfi Achour
Journal:  Environ Sci Pollut Res Int       Date:  2018-10-01       Impact factor: 4.223

9.  The Dietary Fructose:Vitamin C Intake Ratio Is Associated with Hyperuricemia in African-American Adults.

Authors:  Zihe Zheng; Jane L Harman; Josef Coresh; Anna Köttgen; Mara A McAdams-DeMarco; Adolfo Correa; Bessie A Young; Ronit Katz; Casey M Rebholz
Journal:  J Nutr       Date:  2018-03-01       Impact factor: 4.798

10.  Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier; Godela M Fick-Brosnahan
Journal:  Nephrol Dial Transplant       Date:  2012-12-04       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.